Bonnefoy-Bérard N, Vincent C, Revillard J P
Immunology Laboratory, INSERM U80, CNRS URA 1177, UCBL, Lyon, France.
Transplantation. 1991 Mar;51(3):669-73. doi: 10.1097/00007890-199103000-00024.
Antilymphocyte or antithymocyte globulins were shown to be immunosuppressive when administered to recipients of organ transplants as prophylactic or rescue treatment of acute rejection or in patients with acute graft versus host reactions following bone marrow transplantation. Several monoclonal antibodies specific for activation or adhesion molecules of the T lymphocyte surface can also inhibit experimental or clinical allograft reactions. We have investigated the presence of some antibodies, of defined specificity and documented biological activity, in polyclonal antilymphocyte and antithymocyte globulins in order to get further insight into the mechanism of action of these polyclonal antibodies. Using a quantitative immunofluorescence assay by flow cytometry we could estimate the minimal amounts of antibodies to LFA-1 (CD11a and CD18), CD45, CD3, and CD5. Antibodies to HLA-DR, CD2, CD4, CD8, and CD25 were also demonstrated but could not be quantified. Antibodies to beta 2-microglobulin were determined by ELISA. These data suggest that interference with functional lymphocyte surface molecules may account at least in part for the immunosuppressive activity of antilymphocyte and antithymocyte globulins.
抗淋巴细胞球蛋白或抗胸腺细胞球蛋白在给予器官移植受者时，可作为急性排斥反应的预防性或挽救性治疗，或用于骨髓移植后发生急性移植物抗宿主反应的患者，显示出免疫抑制作用。几种针对T淋巴细胞表面激活或黏附分子的单克隆抗体也可抑制实验性或临床同种异体移植反应。我们研究了多克隆抗淋巴细胞球蛋白和抗胸腺细胞球蛋白中一些具有明确特异性和已记录生物学活性的抗体的存在情况，以便进一步深入了解这些多克隆抗体的作用机制。使用流式细胞术定量免疫荧光测定法，我们可以估计针对淋巴细胞功能相关抗原-1（CD11a和CD18）、CD45、CD3和CD5的抗体的最小量。针对人类白细胞抗原-DR、CD2、CD4、CD8和CD25的抗体也得到了证实，但无法进行定量。通过酶联免疫吸附测定法测定了针对β2-微球蛋白的抗体。这些数据表明，干扰功能性淋巴细胞表面分子可能至少部分解释了抗淋巴细胞球蛋白和抗胸腺细胞球蛋白的免疫抑制活性。
